NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale

Contemporary Clinical Trials

Volumn 50, Issue , 2016, Pages 253-264

  Lee, Joshua D ^a   Nunes, Edward V ^b   MPA, Patricia Novo ^a   Bailey, Genie L ^c,d   Brigham, Gregory S ^e   Cohen, Allan J ^f   Fishman, Marc ^g   Ling, Walter ^h   Lindblad, Robert ⁱ   Shmueli Blumberg, Dikla ⁱ   Stablein, Don ⁱ   May, Jeanine ⁱ   Salazar, Dagmar ⁱ   Liu, David ^j   Rotrosen, John ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c BROWN UNIVERSITY   (United States)

^d Stanley Street Treatment & Resources ^*  (United States)

^e ADAPT   (United States)

^f Bay Area Addiction Research and Treatment   (United States)

^g Mountain Manor Treatment Center   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ EMMES CORPORATION   (United States)

^j NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

more..

Author keywords

Buprenorphine naloxone; Clinical trials network; Extended release naltrexone; Medication assisted therapy; Methods or experimental design; Opioid dependence

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; METHADONE; NALTREXONE; NARCOTIC ANTAGONIST;

ALCOHOL CONSUMPTION; ARTICLE; COGNITION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG CRAVING; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG USE; EVIDENCE BASED MEDICINE; EXTENDED DRUG RELEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; OPIATE ADDICTION; OUTCOME ASSESSMENT; OUTPATIENT CARE; PARALLEL DESIGN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SMOKING; TREATMENT DURATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DELAYED RELEASE FORMULATION; ECONOMICS; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NATIONAL HEALTH ORGANIZATION; PROCEDURES; SOCIOECONOMICS; UNITED STATES;

BUPRENORPHINE, NALOXONE DRUG COMBINATION; COMPARATIVE EFFECTIVENESS RESEARCH; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; NATIONAL INSTITUTE ON DRUG ABUSE (U.S.); OPIOID-RELATED DISORDERS; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 84987639408     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2016.08.004     Document Type: Article

References (54)

1. [1] Volkow, N.D., Frieden, T.R., Hyde, P.S., Cha, S.S., Medication-assisted therapies—tackling the opioid-overdose epidemic. N. Engl. J. Med. 370 (2014), 2063–2066.
2. [2] Kreek, M.J., Borg, L., Ducat, E., Ray, B., Pharmacotherapy in the treatment of addiction: methadone. J. Addict. Dis. 29 (2010), 200–216.
3. [3] Mattick, R.P., Kimber, J., Breen, C., Davoli, M., Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. The Cochrane Database of Systematic Reviews, 2008, CD002207.
4. [4] Mattick, R.P., Breen, C., Kimber, J., Davoli, M., Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. The Cochrane Database of Systematic Reviews, 2, 2014, CD002207.
5. [5] Mattick, R.P., Breen, C., Kimber, J., Davoli, M., Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. The Cochrane Database of Systematic Reviews, 2009, CD002209.
6. [6] Nunes, E.V., Rothenberg, J.L., Sullivan, M.A., Carpenter, K.M., Kleber, H.D., Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?. Am. J. Drug Alcohol Abuse 32 (2006), 503–517.
7. [7] Comer, S.D., Sullivan, M.A., Yu, E., et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 63 (2006), 210–218.
8. [8] Krupitsky, E., Zvartau, E., Blokhina, E., et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch. Gen. Psychiatry 69 (2012), 973–981.
9. [9] Tiihonen, J., Krupitsky, E., Verbitskaya, E., et al. Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am. J. Psychiatry 169 (2012), 531–536.
10. [10] Krupitsky, E., Nunes, E.V., Ling, W., Illeperuma, A., Gastfriend, D.R., Silverman, B.L., Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 377 (2011), 1506–1513.
11. [11] Stein, B.D., Gordon, A.J., Sorbero, M., Dick, A.W., Schuster, J., Farmer, C., The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone. Drug Alcohol Depend. 123 (2012), 72–78.
12. [12] Rieckmann, T., Daley, M., Fuller, B.E., Thomas, C.P., McCarty, D., Client and counselor attitudes toward the use of medications for treatment of opioid dependence. J. Subst. Abus. Treat. 32 (2007), 207–215.
13. [13] Fox, A.D., Maradiaga, J., Weiss, L., Sanchez, J., Starrels, J.L., Cunningham, C.O., Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder. Addict. Sci. Clin. Pract., 10, 2015, 2.
14. [14] Rieckmann, T.R., Kovas, A.E., McFarland, B.H., Abraham, A.J., A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment. J. Subst. Abus. Treat. 41 (2011), 374–385.
15. [15] Krupitsky, E., Zvartau, E., Woody, G., Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr. Psychiatry Rep. 12 (2010), 448–453.
16. [16] Brigham, G.S., Feaster, D.J., Wakim, P.G., Dempsey, C.L., Choosing a control group in effectiveness trials of behavioral drug abuse treatments. J. Subst. Abus. Treat. 37 (2009), 388–397.
17. [17] Carroll, K.M., Ball, S.A., Jackson, R., et al. Ten take home lessons from the first 10 years of the CTN and 10 recommendations for the future. Am. J. Drug Alcohol Abuse 37 (2011), 275–282.
18. [18] Nunes, E.V., Ball, S., Booth, R., et al. Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: have we chosen the best designs?. J. Subst. Abus. Treat. 38:Suppl. 1 (2010), S97–112.
19. [19] Feaster, D.J., Mikulich-Gilbertson, S., Brincks, A.M., Modeling site effects in the design and analysis of multi-site trials. Am. J. Drug Alcohol Abuse 37 (2011), 383–391.
20. [20] Lei, H., Nahum-Shani, I., Lynch, K., Oslin, D., Murphy, S.A., A “SMART” design for building individualized treatment sequences. Annu. Rev. Clin. Psychol. 8 (2012), 21–48.
21. [21] Bailey, G.L., Herman, D.S., Stein, M.D., Perceived relapse risk and desire for medication assisted treatment among persons seeking inpatient opiate detoxification. J. Subst. Abus. Treat. 45 (2013), 302–305.
22. [22] Stein, M.D., Anderson, B.J., Bailey, G.L., Preferences for aftercare among persons seeking short-term opioid detoxification. J. Subst. Abus. Treat. 59 (2015), 99–103.
23. [23] Sullivan, M.A., Rothenberg, J.L., Vosburg, S.K., et al. Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial. Am. J. Addict. 15 (2006), 150–159.
24. [24] Carpenter, K.M., Jiang, H., Sullivan, M.A., et al. Betting on change: modeling transitional probabilities to guide therapy development for opioid dependence. Psychol. Addict. Behav. 23 (2009), 47–55.
25. [25] Brooks, A.C., Comer, S.D., Sullivan, M.A., et al. Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment. J. Clin. Psychiatry 71 (2010), 1371–1378.
26. [26] Ling, W., Amass, L., Shoptaw, S., et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 100 (2005), 1090–1100.
27. [27] Sigmon, S.C., Bisaga, A., Nunes, E.V., O'Connor, P.G., Kosten, T., Woody, G., Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. Am. J. Drug Alcohol Abuse 38 (2012), 187–199.
28. [28] Collins, E.D., Kleber, H.D., Whittington, R.A., Heitler, N.E., Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA 294 (2005), 903–913.
29. [29] Alkermes, I., Vivitrol Product Package Insert and Medication Guide. 2013.
30. [30] Kampman, K., Jarvis, M., American Society of Addiction Medicine (ASAM) National Practice Guideline for the use of medications in the treatment of addiction involving opioid use. Journal of Addiction Medicine 9 (2015), 358–367.
31. [31] Anton, R.F., O'Malley, S.S., Ciraulo, D.A., et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295 (2006), 2003–2017.
32. [32] Wolfe, D.C., Dasgupta, N., Bruce, R.D., Wodak, A., Authors’ reply. Lancet, 378, 2011, 666.
33. [33] Wolfe, D., Carrieri, M.P., Dasgupta, N., Wodak, A., Newman, R., Bruce, R.D., Concerns about injectable naltrexone for opioid dependence. Lancet 377 (2011), 1468–1470.
34. [34] Sullivan, M.A., Garawi, F., Bisaga, A., et al. Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend. 91 (2007), 289–292.
35. [35] Lee, J.D., Friedmann, P.D., Kinlock, T.W., et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N. Engl. J. Med. 374 (2016), 1232–1242.
36. [36] Lee, J.D., Grossman, E., DiRocco, D., Gourevitch, M.N., Home buprenorphine/naloxone induction in primary care. J. Gen. Intern. Med. 24 (2009), 226–232.
37. [37] Liebschutz, J.M., Crooks, D., Herman, D., et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA internal medicine 174 (2014), 1369–1376.
38. [38] Timko, C., Schultz, N.R., Cucciare, M.A., Vittorio, L., Garrison-Diehn, C., Retention in medication-assisted treatment for opiate dependence: a systematic review. J. Addict. Dis. 35 (2016), 22–35.
39. [39] Trivedi, M.H., Wisniewski, S.R., Morris, D.W., et al. Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk. J. Clin. Psychiatry 72 (2011), 757–764.
40. [40] Sobell, J.L., Sobell, M.B., Timeline follow-back: a technique for assessing self-reported alcohol consumption. Litten, R., Allen, J., (eds.) Measuring Alcohol Consumption, 1992, The Human Press, Inc.
41. [41] Fals-Stewart, W., O'Farrell, T.J., Freitas, T.T., McFarlin, S.K., Rutigliano, P., The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. J. Consult. Clin. Psychol. 68 (2000), 134–144.
42. [42] McLellan, A.T., Kushner, H., Metzger, D., et al. The fifth edition of the addiction severity index. J. Subst. Abus. Treat. 9 (1992), 199–213.
43. [43] Hamilton, M., A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960), 56–62.
44. [44] Handelsman, L., Cochrane, K.J., Aronson, M.J., Ness, R., Rubinstein, K.J., Kanof, P.D., Two new rating scales for opiate withdrawal. Am. J. Drug Alcohol Abuse 13 (1987), 293–308.
45. [45] Fagerstrom, K.O., Schneider, N.G., Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire. J. Behav. Med. 12 (1989), 159–182.
46. [46] Heatherton, T.F., Kozlowski, L.T., Frecker, R.C., Fagerstrom, K.O., The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br. J. Addict. 86 (1991), 1119–1127.
47. [47] Navaline, H.A., Snider, E.C., Petro, C.J., et al. Preparations for AIDS vaccine trials. An automated version of the Risk Assessment Battery (RAB): enhancing the assessment of risk behaviors. AIDS Research and Human Retroviruses 10:Suppl. 2 (1994), S281–S283.
48. [48] Sanchez-Cubillo, I., Perianez, J.A., Adrover-Roig, D., et al. Construct validity of the Trail Making Test: role of task-switching, working memory, inhibition/interference control, and visuomotor abilities. Journal of the International Neuropsychological Society 15 (2009), 438–450.
49. [49] Jensen, A.R., Rohwer, W.D. Jr., The Stroop color-word test: a review. Acta Psychol. 25 (1966), 36–93.
50. [50] Rabin, R., de Charro, F., EQ-5D: a measure of health status from the EuroQol Group. Ann. Med. 33 (2001), 337–343.
51. [51] van der Zanden, B.P., Dijkgraaf, M.G., Blanken, P., de Borgie, C.A., van Ree, J.M., van den Brink, W., Validity of the EQ-5D as a generic health outcome instrument in a heroin-dependent population. Drug Alcohol Depend. 82 (2006), 111–118.
52. [52] Wallihan, D.B., Stump, T.E., Callahan, C.M., Accuracy of self-reported health services use and patterns of care among urban older adults. Med. Care 37 (1999), 662–670.
53. [53] Harlow, S.D., Linet, M.S., Agreement between questionnaire data and medical records. The evidence for accuracy of recall. Am. J. Epidemiol. 129 (1989), 233–248.
54. [54] Roberts, R.O., Bergstralh, E.J., Schmidt, L., Jacobsen, S.J., Comparison of self-reported and medical record health care utilization measures. J. Clin. Epidemiol. 49 (1996), 989–995.